Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD

Data ReadoutpositiveOzempicMounjaroPositive

AI Analysis

Summary

Real-world analysis presented at EASD showed Novo Nordisk's Ozempic (semaglutide) 2 mg was associated with a statistically significant 6% lower risk of major adverse cardiovascular events compared to switching to Mounjaro (tirzepatide) in adults with type 2 diabetes.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Semaglutide 2 mg associated with statistically significant 6% lower risk of major adverse cardiovascular events (death, heart attack, stroke) compared to switching to tirzepatide in real-world analysis

Importance:6/10

Sentiment:

0.65

cardiovascularreal-world evidenceEASD conferencetype 2 diabetescomparative efficacy

Related Companies

$NVO

Read the original article

Published by PR Newswire Pharma on September 29, 2026 10:00 AM

Read Original